Nykode Therapeutics AS Statistics
Total Valuation
VACBF has a market cap or net worth of 86.71 million. The enterprise value is -36.02 million.
| Market Cap | 86.71M |
| Enterprise Value | -36.02M |
Important Dates
The last earnings date was Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +8.66% |
| Shares Change (QoQ) | +4.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 149.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.47 |
| PB Ratio | 0.64 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.93 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.70 |
Financial Position
The company has a current ratio of 12.87, with a Debt / Equity ratio of 0.03.
| Current Ratio | 12.87 |
| Quick Ratio | 12.78 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -257.08 |
Financial Efficiency
Return on equity (ROE) is -25.25% and return on invested capital (ROIC) is -19.08%.
| Return on Equity (ROE) | -25.25% |
| Return on Assets (ROA) | -16.70% |
| Return on Invested Capital (ROIC) | -19.08% |
| Return on Capital Employed (ROCE) | -33.47% |
| Revenue Per Employee | 67,338 |
| Profits Per Employee | -285,449 |
| Employee Count | 139 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.01% in the last 52 weeks. The beta is 1.42, so VACBF's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -78.01% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 13.80 |
| Average Volume (20 Days) | 2,142 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, VACBF had revenue of 9.16 million and -38.82 million in losses. Loss per share was -0.12.
| Revenue | 9.16M |
| Gross Profit | 9.16M |
| Operating Income | -48.33M |
| Pretax Income | -45.51M |
| Net Income | -38.82M |
| EBITDA | -47.59M |
| EBIT | -48.33M |
| Loss Per Share | -0.12 |
Balance Sheet
The company has 115.40 million in cash and 3.44 million in debt, giving a net cash position of 111.96 million.
| Cash & Cash Equivalents | 115.40M |
| Total Debt | 3.44M |
| Net Cash | 111.96M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 136.21M |
| Book Value Per Share | 0.42 |
| Working Capital | 107.97M |
Cash Flow
In the last 12 months, operating cash flow was -51.22 million and capital expenditures -71,000, giving a free cash flow of -51.29 million.
| Operating Cash Flow | -51.22M |
| Capital Expenditures | -71,000 |
| Free Cash Flow | -51.29M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -527.75% |
| Pretax Margin | -496.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VACBF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.66% |
| Shareholder Yield | -8.66% |
| Earnings Yield | -44.77% |
| FCF Yield | -59.15% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
VACBF has an Altman Z-Score of 11.8.
| Altman Z-Score | 11.8 |
| Piotroski F-Score | n/a |